Initial information for this spontaneous case, AER number 1180265, was received on 15/Jan/2013 from a 
pharmacist and concerns a 66 years elderly female patient who was treated with BEVACIZUMAB (Avastin), 
CARBOPLATIN, PACLITAXEL (TAXOL) and PEMETREXED DISODIUM for NON SMALL CELL LUNG CANCER. 
No medical history and concurrent conditions were reported. No concomitant medication and past drugs were 
reported. 
On an unspecified date, the patient started therapy with BEVACIZUMAB (route, form, dose and frequency: not 
reported), CARBOPLATIN (route, form, dose and frequency: not reported), PACLITAXEL (route, form, dose and 
frequency: not reported) and PEMETREXED DISODIUM (route, form, dose and frequency: not reported). On an 
unspecified date, the patient developed INTERSTITIAL PNEUMONITIS. It was reported that, the patient received 8 
cycle of CARBOPLATIN, PACLITAXEL and BEVACIZUMAB followed by BEVACIZUMAB and PEMETREXED 
DISODIUM maintenance therapy. It was also reported that, the patient received maintenance therapy for six 
months. 
There was insufficient information regarding outcome of INTERSTITIAL PNEUMONITIS and therapy ongoing 
status with BEVACIZUMAB, CARBOPLATIN, PACLITAXEL and PEMETREXED DISODIUM. 
The reporter assessed the INTERSTITIAL PNEUMONITIS as non serious. 
The company assessed the INTERSTITIAL PNEUMONITIS as medically significant. 
The reporter did not provided the causal relationship of INTERSTITIAL PNEUMONITIS with BEVACIZUMAB, 
CARBOPLATIN, PACLITAXEL and PEMETREXED DISODIUM. 
No further information was provided.